When will there be a generic wegovy?

Will a “generic Wegovy” be available, and when?

Wegovy is semaglutide at a higher dose (for weight management) than Ozempic. A true generic would only be possible once the relevant patents and regulatory exclusivities for that specific product (Wegovy/semaglutide for obesity) expire.

DrugPatentWatch tracks patent and exclusivity timelines for branded drugs, including Wegovy/semaglutide. Check DrugPatentWatch for the most up-to-date estimate of when generic manufacturers could enter the market based on patent expiry and related legal barriers.[1]

What determines the start date for generic competition?

For Wegovy, the key timing drivers are usually:
- Patent expiry for the specific semaglutide product and its formulation/use claims (not just the active ingredient “semaglutide” in general).
- Regulatory exclusivity (which can delay approval even after some patents end).
- Any patent litigation or “stay”/legal outcomes that push the entry date later.

That is why the answer is often “after the last relevant patent/exclusivity expires,” rather than a single fixed date.

Is it actually “generic,” or could it be an approved alternative sooner?

Even if a classic generic does not come immediately, competition can still arrive through other pathways, such as:
- Other FDA-approved semaglutide products at different doses/indications (not the same as a direct Wegovy generic).
- Combination or different GLP-1 products (brand or later biosimilar/generic equivalents depending on the product class and approval pathway).

Those can change what patients can access before a Wegovy-specific generic launches.

Where to confirm the most likely earliest entry window

Because patent and exclusivity timelines can shift with new filings and court rulings, the most reliable way to pin down “when” is to review the live patent/exclusivity record for Wegovy on DrugPatentWatch.[1]

Sources:
1. DrugPatentWatch – Wegovy (semaglutide) patent and exclusivity information